Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Uniqure N.V.. (8/17/16). "Press Release: Uniqure to Present at Upcoming Investor Conferences in September". Lexington, MA & Amsterdam.

Organisations Organisation Uniqure N.V. (Nasdaq: QURE)
  Group Uniqure (Group)
  Organisation 2 Citigroup (Group)
Products Product Citi’s 11th Annual Biotech Conference 2016 Boston
  Product 2 Rodman & Renshaw Annual Global Investment Conference 2016 New York
Index terms Index term Uniqure–Citigroup: investor conference, 201609 supply service Uniqure presents at Citi’s 11th Annual Biotech Conference
  Index term 2 Uniqure–Rodman & Renshaw: investor conference, 201609 supply service Uniqure presents at Rodman & Renshaw Global Investment Conference in NY
Persons Person Meyer, Christian (Uniqure 201310– CMO before Cardoz AB + Symphogen A/S + Zymenex A/S + Novo Nordisk A/S)
  Person 2 Kapusta, Matthew (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew Orthopaedics)

uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that members of its leadership team will present an overview of the company’s programs and progress at several upcoming investor conferences. These meetings include the following:

CITI 11th Annual Biotech Conference
Venue: The Mandarin Oriental Hotel, Boston MA
Presenter: Harald Petry, Ph.D., Chief Scientific Officer
Title, Date and Time: “Gene Therapy, A New Era” panel discussion, Wednesday, September 7, 1:00 p.m. EDT

Rodman & Renshaw 18th Annual Global Investment Conference
Venue: The Lotte New York Palace Hotel, New York City
Presenter: Matthew Kapusta, Chief Financial Officer
Date and Time: Monday, September 12, 3:50 p.m. EDT

Leerink Partners Rountable Series: Rare Disease & Immuno-Oncology
Venue: The Lotte New York Palace Hotel, New York City
Presenter: Christian Meyer, M.D., Chief Medical Officer
Date and Time: Wednesday, September 28, 2:35 p.m. EDT

The webcasts for the Rodman & Renshaw 18th Annual Global Investment Conference and the Leerink Partners Roundtable Series, also can be accessed by the link displayed in the “Events” section on the “Media” page of the uniQure website at: The replay of the webcast will be available one hour after the conclusion of the live events and archived on the uniQure website for at least 30 days following the webcast.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases.

uniQure Forward-Looking Statement

This press release contains forward-looking statements. All statements other than statements of historical fact are forwardlooking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators’ clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452

Eva Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79

Record changed: 2017-07-02


Picture [iito] – Putting Information into Context 600x60px

More documents for Uniqure (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] – Putting Information into Context 600x60px

» top